Adverum Biotechnologies Analyst Ratings
Adverum Biotechnologies Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 227.87% | Truist Securities | → $6 | Reiterates | Buy → Buy |
| 08/11/2023 | 118.58% | Chardan Capital | $2 → $4 | Upgrades | Neutral → Buy |
| 03/07/2023 | 9.29% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
| 11/11/2022 | 9.29% | Chardan Capital | $2.5 → $2 | Maintains | Neutral |
| 11/11/2022 | 63.93% | RBC Capital | $5 → $3 | Maintains | Sector Perform |
| 08/12/2022 | 36.61% | Chardan Capital | $3 → $2.5 | Maintains | Neutral |
| 07/07/2022 | 118.58% | Truist Securities | $3 → $4 | Upgrades | Hold → Buy |
| 07/23/2021 | 63.93% | Chardan Capital | $5 → $3 | Maintains | Neutral |
| 07/23/2021 | 63.93% | Cantor Fitzgerald | $23 → $3 | Downgrades | Overweight → Neutral |
| 07/23/2021 | 9.29% | SVB Leerink | $5 → $2 | Maintains | Market Perform |
| 05/03/2021 | 173.22% | SVB Leerink | → $5 | Downgrades | Outperform → Market Perform |
| 04/29/2021 | 227.87% | RBC Capital | → $6 | Downgrades | Outperform → Sector Perform |
| 04/29/2021 | 173.22% | Chardan Capital | $20 → $5 | Downgrades | Buy → Neutral |
| 04/29/2021 | 391.8% | Truist Securities | $30 → $9 | Downgrades | Buy → Hold |
| 04/29/2021 | 501.09% | SVB Leerink | $21 → $11 | Maintains | Outperform |
| 11/12/2020 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 08/11/2020 | 1047.54% | SVB Leerink | $20 → $21 | Maintains | Outperform |
| 05/13/2020 | 1211.48% | RBC Capital | → $24 | Initiates Coverage On | → Outperform |
| 05/05/2020 | 1047.54% | SunTrust Robinson Humphrey | → $21 | Upgrades | Hold → Buy |
| 05/05/2020 | 992.9% | SVB Leerink | $17 → $20 | Maintains | Outperform |
| 04/28/2020 | 828.96% | Goldman Sachs | → $17 | Initiates Coverage On | → Buy |
| 03/16/2020 | 828.96% | SVB Leerink | → $17 | Initiates Coverage On | → Outperform |
| 02/10/2020 | 992.9% | Chardan Capital | $10 → $20 | Upgrades | Neutral → Buy |
| 02/10/2020 | 1047.54% | Cantor Fitzgerald | $8 → $21 | Upgrades | Neutral → Overweight |
| 01/13/2020 | 992.9% | Piper Sandler | $14 → $20 | Reiterates | → Overweight |
| 09/13/2019 | 337.16% | SunTrust Robinson Humphrey | $12 → $8 | Maintains | Hold |
| 06/14/2019 | — | Raymond James | Reinstates | → Market Perform | |
| 11/05/2018 | 118.58% | Cantor Fitzgerald | $12 → $4 | Downgrades | Overweight → Neutral |
| 11/02/2018 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 11/02/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 09/21/2018 | 555.74% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/05/2023 | 227.87% | Truist证券 | →$6 | 重申 | 购买→购买 |
| 2023年08月11日 | 118.58% | 查尔丹资本 | $2→$4 | 升级 | 中性→购买 |
| 03/07/2023 | 9.29% | 拉登堡·塔尔曼 | →$2 | 开始承保 | →购买 |
| 2022年11月11日 | 9.29% | 查尔丹资本 | $2.5→$2 | 维护 | 中性 |
| 2022年11月11日 | 63.93% | 加拿大皇家银行资本 | $5→$3 | 维护 | 行业表现 |
| 2022年08月12日 | 36.61% | 查尔丹资本 | $3→$2.5 | 维护 | 中性 |
| 07/07/2022 | 118.58% | Truist证券 | $3→$4 | 升级 | 持有→购买 |
| 07/23/2021 | 63.93% | 查尔丹资本 | $5→$3 | 维护 | 中性 |
| 07/23/2021 | 63.93% | 康托·菲茨杰拉德 | $23→$3 | 评级下调 | 超重→中性 |
| 07/23/2021 | 9.29% | SVB Leerink | $5→$2 | 维护 | 市场表现 |
| 05/03/2021 | 173.22% | SVB Leerink | →$5 | 评级下调 | 跑赢→市场表现 |
| 04/29/2021 | 227.87% | 加拿大皇家银行资本 | →$6 | 评级下调 | 跑赢→板块表现 |
| 04/29/2021 | 173.22% | 查尔丹资本 | $20→$5 | 评级下调 | 购买→中性 |
| 04/29/2021 | 391.8% | Truist证券 | $30→$9 | 评级下调 | 购买→Hold |
| 04/29/2021 | 501.09% | SVB Leerink | $21→$11 | 维护 | 跑赢大盘 |
| 2020年11月12日 | - | 雷蒙德·詹姆斯 | 升级 | 表现逊于→市场表现 | |
| 2020年08月11日 | 1047.54% | SVB Leerink | $20→$21 | 维护 | 跑赢大盘 |
| 2020/05/13 | 1211.48% | 加拿大皇家银行资本 | →$24 | 开始承保 | →跑赢大盘 |
| 05/05/2020 | 1047.54% | SunTrust Robinson Humphrey | →$21 | 升级 | 持有→购买 |
| 05/05/2020 | 992.9% | SVB Leerink | $17→$20 | 维护 | 跑赢大盘 |
| 04/28/2020 | 828.96% | 高盛 | →$17 | 开始承保 | →购买 |
| 03/16/2020 | 828.96% | SVB Leerink | →$17 | 开始承保 | →跑赢大盘 |
| 02/10/2020 | 992.9% | 查尔丹资本 | $10→$20 | 升级 | 中性→购买 |
| 02/10/2020 | 1047.54% | 康托·菲茨杰拉德 | $8→$21 | 升级 | 中性→超重 |
| 2020/01/13 | 992.9% | 派珀·桑德勒 | $14→$20 | 重申 | →超重 |
| 2019年09月13日 | 337.16% | SunTrust Robinson Humphrey | $12→$8 | 维护 | 保持 |
| 2019年06月14日 | - | 雷蒙德·詹姆斯 | 恢复 | →市场表现 | |
| 2018年11月05日 | 118.58% | 康托·菲茨杰拉德 | $12→$4 | 评级下调 | 超重→中性 |
| 11/02/2018 | - | SunTrust Robinson Humphrey | 评级下调 | 购买→Hold | |
| 11/02/2018 | - | 雷蒙德·詹姆斯 | 评级下调 | 跑赢→市场表现 | |
| 2018年09月21日 | 555.74% | 康托·菲茨杰拉德 | →$12 | 开始承保 | →超重 |
What is the target price for Adverum Biotechnologies (ADVM)?
Adverum BioTechnologies(ADVM)的目标价格是多少？
The latest price target for Adverum Biotechnologies (NASDAQ: ADVM) was reported by Truist Securities on September 5, 2023. The analyst firm set a price target for $6.00 expecting ADVM to rise to within 12 months (a possible 227.87% upside). 5 analyst firms have reported ratings in the last year.
Adverum BioTechnologies(纳斯达克：advm)的最新目标价是由Truist证券于2023年9月5日报道的。这家分析公司将目标价定为6美元，预计ADM将在12个月内升至(可能上涨227.87%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?
Adverum BioTechnologies(ADVM)的最新分析师评级是什么？
The latest analyst rating for Adverum Biotechnologies (NASDAQ: ADVM) was provided by Truist Securities, and Adverum Biotechnologies reiterated their buy rating.
分析师对Adverum BioTechnologies(纳斯达克代码：ADVM)的最新评级由Truist Securities提供，Adverum BioTechnologies重申了其买入评级。
When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?
Adverum BioTechnologies(ADVM)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Adverum BioTechnologies的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Adverum BioTechnologies的上一次评级是在2023年9月5日提交的，因此您应该预计下一次评级将在2024年9月5日左右的某个时候提供。
Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?
分析师对Adverum BioTechnologies(ADVM)的评级正确吗？
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adverum Biotechnologies (ADVM) is trading at is $1.83, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Adverum BioTechnologies(ADVM)评级被重申，目标价在0.00美元至6.00美元之间。Adverum BioTechnologies(ADVM)目前的股价为1.83美元，在分析师的预测范围内。